The PIK3CG antibody targets the catalytic gamma subunit of phosphoinositide 3-kinase (PI3Kγ), encoded by the *PIK3CG* gene. PI3Kγ, a class IB PI3K, plays a critical role in signaling pathways regulating cell growth, survival, motility, and immune responses. Unlike other PI3K isoforms, PI3Kγ is primarily expressed in hematopoietic cells and is activated by G protein-coupled receptors (GPCRs) through interaction with Gβγ subunits. It converts phosphatidylinositol-4.5-bisphosphate (PIP2) to phosphatidylinositol-3.4.5-trisphosphate (PIP3), recruiting downstream effectors like AKT and mTOR.
PIK3CG antibodies are essential tools for studying PI3Kγ expression, localization, and function in immune regulation, inflammation, and cancer. They are used in techniques such as Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to assess protein levels in cell lines, tissues, or primary immune cells. Dysregulation of PI3Kγ is linked to autoimmune diseases, chronic inflammation, and tumor microenvironments, making these antibodies valuable in therapeutic research, particularly for inhibitors targeting PI3Kγ in oncology and immunology.
Antibodies against PIK3CG often recognize specific epitopes within the kinase or helical domains, with validation including knockout controls to confirm specificity. Researchers select antibodies based on host species, clonality (monoclonal/polyclonal), and compatibility with experimental assays. Reliable PIK3CG antibodies aid in elucidating mechanisms of PI3Kγ-driven pathologies and evaluating targeted therapies.